Napajen Pharma Inc., of Burlingame, Calif., closed a series C financing of $12.4 million, led by existing investor INCJ Ltd. with participation by existing investor Mitsui & Co. Global Investment and new investor P&D Directions Inc. Napajen plans to use the funds to complete an ongoing phase I study of NJA-730, an anti-CD40 small interfering RNA delivered using the company's beta-glucan technology.